CTLA4 and uveal melanoma: Some features of uveal melanoma, such as the privileged site of the eye, the immune suppressive microenviroment of the liver, and the low mutational burden associated with several mechanisms of immune escape can explain the poor results obtained with anti-PD-1 and anti-CTLA-4 agents in metastatic uveal melanoma.